Abbott Laboratories Gross Margin 2006-2019 | ABT
Current and historical gross margin for Abbott Laboratories (ABT) over the last 10 years. The current gross profit margin for Abbott Laboratories as of March 31, 2019 is %.
| Abbott Laboratories Gross Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Gross Profit | Gross Margin |
| 2019-03-31 | $30.72B | $17.92B | 58.34% |
| 2018-12-31 | $30.58B | $17.87B | 58.45% |
| 2018-09-30 | $30.40B | $17.61B | 57.91% |
| 2018-06-30 | $29.58B | $17.07B | 57.71% |
| 2018-03-31 | $28.45B | $16.03B | 56.36% |
| 2017-12-31 | $27.39B | $14.98B | 54.70% |
| 2017-09-30 | $25.13B | $13.63B | 54.21% |
| 2017-06-30 | $23.61B | $12.69B | 53.75% |
| 2017-03-31 | $22.30B | $12.29B | 55.09% |
| 2016-12-31 | $20.85B | $11.76B | 56.39% |
| 2016-09-30 | $20.71B | $11.79B | 56.93% |
| 2016-06-30 | $20.56B | $11.68B | 56.83% |
| 2016-03-31 | $20.39B | $11.59B | 56.82% |
| 2015-12-31 | $20.41B | $11.66B | 57.13% |
| 2015-09-30 | $20.57B | $11.70B | 56.85% |
| 2015-06-30 | $20.50B | $11.55B | 56.32% |
| 2015-03-31 | $20.39B | $11.36B | 55.74% |
| 2014-12-31 | $20.25B | $11.03B | 54.47% |
| 2014-09-30 | $18.90B | $10.06B | 53.21% |
| 2014-06-30 | $18.65B | $9.87B | 52.92% |
| 2014-03-31 | $19.03B | $10.00B | 52.53% |
| 2013-12-31 | $19.66B | $10.46B | 53.23% |
| 2013-09-30 | $18.84B | $9.92B | 52.68% |
| 2013-06-30 | $19.28B | $10.13B | 52.55% |
| 2013-03-31 | $19.14B | $10.17B | 53.13% |
| 2012-12-31 | $19.05B | $10.15B | 53.29% |
| 2012-09-30 | $26.24B | $15.18B | 57.86% |
| 2012-06-30 | $30.79B | $18.25B | 59.27% |
| 2012-03-31 | $35.09B | $21.05B | 59.99% |
| 2011-12-31 | $38.85B | $23.31B | 60.00% |
| 2011-09-30 | $38.44B | $22.69B | 59.03% |
| 2011-06-30 | $37.30B | $21.78B | 58.40% |
| 2011-03-31 | $36.51B | $21.32B | 58.39% |
| 2010-12-31 | $35.17B | $20.50B | 58.30% |
| 2010-09-30 | $33.99B | $19.58B | 57.62% |
| 2010-06-30 | $33.08B | $19.05B | 57.60% |
| 2010-03-31 | $31.74B | $18.14B | 57.13% |
| 2009-12-31 | $30.76B | $17.56B | 57.06% |
| 2009-09-30 | $29.92B | $17.32B | 57.88% |
| 2009-06-30 | $29.66B | $17.07B | 57.53% |
| 2009-03-31 | $29.48B | $16.89B | 57.30% |
| 2008-12-31 | $29.53B | $16.92B | 57.29% |
| 2008-09-30 | $28.80B | $16.20B | 56.27% |
| 2008-06-30 | $27.68B | $15.57B | 56.26% |
| 2008-03-31 | $26.74B | $14.94B | 55.90% |
| 2007-12-31 | $25.92B | $14.49B | 55.93% |
| 2007-09-30 | $25.52B | $13.98B | 54.78% |
| 2007-06-30 | $24.71B | $13.65B | 55.23% |
| 2007-03-31 | $23.84B | $13.20B | 55.34% |
| 2006-12-31 | $22.48B | $12.66B | 56.34% |
| 2006-09-30 | $21.70B | $12.36B | 56.93% |
| 2006-06-30 | $21.51B | $11.88B | 55.22% |
| 2006-03-31 | $21.54B | $11.66B | 54.14% |
| 2005-12-31 | $22.34B | $11.70B | 52.36% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $133.667B | $30.578B |
| Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medtronic (MDT) | Ireland | $114.132B | 16.69 |
| Stryker (SYK) | United States | $69.756B | 24.90 |
| Boston Scientific (BSX) | United States | $49.905B | 24.25 |
| Baxter (BAX) | United States | $39.019B | 25.03 |
| Zimmer Biomet Holdings (ZBH) | United States | $25.114B | 16.07 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.786B | 0.00 |
| Canopy Growth (CGC) | Canada | $16.315B | 0.00 |
| ResMed (RMD) | United States | $14.544B | 27.58 |
| Aurora Cannabis (ACB) | Canada | $9.179B | 64.71 |
| Bio-Rad Laboratories (BIO) | United States | $8.795B | 50.45 |
| Perrigo (PRGO) | Ireland | $6.734B | 10.92 |
| Hill-Rom Holdings (HRC) | United States | $6.397B | 19.79 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $4.994B | 0.00 |
| Insulet (PODD) | United States | $4.964B | 1664.20 |
| ICU Medical (ICUI) | United States | $4.636B | 28.71 |
| Haemonetics (HAE) | United States | $4.354B | 38.62 |
| Hutchison China MediTech (HCM) | China | $3.962B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $3.443B | 0.00 |
| Neogen (NEOG) | United States | $3.004B | 48.85 |
| NuVasive (NUVA) | United States | $2.967B | 25.77 |
| Quidel (QDEL) | United States | $2.487B | 22.25 |
| National Vision Holdings (EYE) | United States | $2.276B | 44.77 |
| Aphria (APHA) | $1.957B | 0.00 | |
| HEXO (HEXO) | $1.474B | 0.00 | |
| Phibro Animal Health (PAHC) | United States | $1.338B | 19.24 |
| VAREX IMAGING (VREX) | United States | $1.234B | 24.16 |
| Cardiovascular Systems (CSII) | United States | $1.212B | 870.25 |
| AtriCure (ATRC) | United States | $1.076B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $0.957B | 25.86 |
| Omeros (OMER) | United States | $0.929B | 0.00 |
| PetIQ (PETQ) | United States | $0.865B | 24.76 |
| Cerus (CERS) | United States | $0.831B | 0.00 |
| MacroGenics (MGNX) | United States | $0.820B | 0.00 |
| NanoString Technologies (NSTG) | United States | $0.781B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.725B | 24.66 |
| TG Therapeutics (TGTX) | United States | $0.717B | 0.00 |
| Evolus (EOLS) | United States | $0.708B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.589B | 25.68 |
| Surmodics (SRDX) | United States | $0.584B | 84.94 |
| LeMaitre Vascular (LMAT) | United States | $0.555B | 26.37 |
| Meridian Bioscience (VIVO) | United States | $0.538B | 16.02 |
| Quanterix (QTRX) | United States | $0.515B | 0.00 |
| Insys Therapeutics (INSY) | United States | $0.332B | 0.00 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.329B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.326B | 21.19 |
| BioLife Solutions (BLFS) | United States | $0.302B | 124.61 |
| Vapotherm (VAPO) | United States | $0.287B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.270B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.228B | 0.00 |
| Owens & Minor (OMI) | United States | $0.213B | 2.91 |
| Zynex (ZYXI) | United States | $0.172B | 18.38 |
| Bovie Medical (APYX) | United States | $0.140B | 0.00 |
| Chimerix (CMRX) | United States | $0.138B | 0.00 |
| Fonar (FONR) | United States | $0.128B | 6.85 |
| Chembio Diagnostics (CEMI) | United States | $0.122B | 0.00 |
| Surface Oncology (SURF) | United States | $0.114B | 0.00 |
| United-Guardian (UG) | United States | $0.089B | 20.32 |
| Female Health (VERU) | United States | $0.088B | 0.00 |
| InfuSystems Holdings (INFU) | United States | $0.085B | 0.00 |
| Neurotrope (NTRP) | United States | $0.075B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.069B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.067B | 19.86 |
| GUARDION HEALTH (GHSI) | United States | $0.054B | 0.00 |
| ImmuCell (ICCC) | United States | $0.045B | 0.00 |
| Senestech (SNES) | United States | $0.036B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.031B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.024B | 0.00 |
| Myomo (MYO) | United States | $0.021B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.017B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.011B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.007B | 13.00 |
